{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:01:38Z","timestamp":1787788898088,"version":"build-2784847793"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) are associated with different immune-related adverse events (irAEs), but there is limited evidence regarding the association between urinary incontinence and ICIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We described the case of a patient experiencing urinary incontinence who later experienced a series of irAEs such as myocarditis, myositis, and neurologic diseases while on ICI treatment in our hospital. In addition, we queried the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from the third quarter of 2010 to the third quarter of 2020 to perform a retrospective study to characterize the clinical features of urinary incontinence associated with ICIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>In the FAERS study, 59 cases of ICI-related urinary incontinence were retrieved, and approximately 32.2% of the cases were fatal. Combination therapy with nervous system drugs and age &amp;gt;80 years old were the significant risk factors for fatal outcomes. Among these cases of ICI-related urinary incontinence, 40.7% (n = 24) occurred concomitantly with other adverse events, especially, neurological (fifteen cases), cardiovascular (seven cases), musculoskeletal (six cases), and urological disorders (five cases). Five cases had an overlapping syndrome similar to our case report, including one case of myasthenia gravis with myocarditis and another of myasthenic syndrome with polymyositis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICI-related urinary incontinence might be a signal of fatal neuromuscular irAEs, especially when it occurs concomitantly with ICI-associated neuromuscular\u2013cardiovascular syndrome. Clinicians should be aware of the occurrence of urinary incontinence to identify potentially lethal irAEs in the early phase.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.954468","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:26:08Z","timestamp":1662967568000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study"],"prefix":"10.3389","volume":"12","author":[{"given":"Yizhang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoling","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B4","article-title":"Urinary incontinence in women: Evaluation and management","volume":"100","author":"Hu","year":"2019","journal-title":"Am Fam Physician"},{"key":"B5","volume-title":"Campbell-Walsh Urology e-book","author":"Partin","year":"2015"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-454","article-title":"Immunotherapy-related skeletal muscle weakness in cancer patients: A case series","volume":"10","author":"Ng","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000167","article-title":"Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: An unusual presentation of a rare complication of immunotherapy","volume":"40","author":"Kelly Wu","year":"2017","journal-title":"J Immunother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci Data"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825070-00001","article-title":"Drug-induced urinary incontinence","volume":"25","author":"Tsakiris","year":"2008","journal-title":"Drugs Aging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: A systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13266","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system","volume":"11","author":"Shi","year":"2020","journal-title":"Thorac Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000494078","article-title":"Lambert-Eaton Myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani","year":"2018","journal-title":"Case Rep Neurol"},{"key":"B16","article-title":"Neurologic urinary and faecal incontinence","volume-title":"Incontinence","author":"Wyndaele","year":"2005"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)50709-0","article-title":"The urodynamic aspects of the Guillain-Barr\u00e9 syndrome","volume":"131","author":"Wheeler","year":"1984","journal-title":"J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.5.649","article-title":"Micturitional disturbance in patients with Guillain-Barr\u00e9 syndrome","volume":"63","author":"Sakakibara","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-017-0751-8","article-title":"Psychosis secondary to an incidental teratoma: a \u201cheads-up\u201d for psychiatrists and gynecologists","volume":"20","author":"Voice","year":"2017","journal-title":"Arch Womens Ment Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000226119","article-title":"Cerebellar ataxia and overactive bladder after encephalitis affecting the cerebellum","volume":"1","author":"Sugiyama","year":"2009","journal-title":"Case Rep Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61760-9","article-title":"Multiple sclerosis and the urologist","volume":"161","author":"Litwiller","year":"1999","journal-title":"J Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13010","article-title":"Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients\u2019 quality of life","volume":"23","author":"Zecca","year":"2016","journal-title":"Eur J Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.10.112","article-title":"Nocturnal urinary disorders and multiple sclerosis: Clinical and urodynamic study of 309 patients","volume":"197","author":"Mauruc","year":"2017","journal-title":"J Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000513234","article-title":"Multiple sclerosis and incidence of urinary and fecal incontinence in almost 9,000 patients followed up for up to 10 years in Germany","volume":"55","author":"Jacob","year":"2021","journal-title":"Neuroepidemiology"},{"key":"B25","article-title":"Lower urinary tract symptoms and depression in patients with multiple sclerosis","volume":"32","author":"Tudor","year":"2020","journal-title":"Psychiatr Danub"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000514825","article-title":"Lower urinary tract symptoms in myasthenia gravis","volume":"13","author":"Tateno","year":"2021","journal-title":"Case Rep Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14873","article-title":"The impact of myasthenia gravis on lower urinary tract functions","volume":"75","author":"Akan","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.1998.tb00276.x","article-title":"Detrusor areflexia in a patient with myasthenia gravis","volume":"5","author":"Sandler","year":"1998","journal-title":"Int J Urol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(00)00460-3","article-title":"Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine","volume":"183","author":"Satoh","year":"2001","journal-title":"J Neurol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab397","article-title":"Sexual function in patients with idiopathic inflammatory myopathies: A cross-sectional study","volume":"60","author":"He\u0159m\u00e1nkov\u00e1","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro0874","article-title":"Interstitial cystitis and systemic autoimmune diseases","volume":"4","author":"Van De Merwe","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12211","article-title":"Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma","volume":"3","author":"Ueki","year":"2020","journal-title":"IJU Case Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2017.12.006","article-title":"Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor","volume":"17","author":"Shimatani","year":"2018","journal-title":"Urol Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2021.100101","article-title":"A case of severe interstitial cystitis associated with pembrolizumab","volume":"4","author":"El Husseini","year":"2021","journal-title":"Curr Probl Cancer: Case Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: A retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J Neuro Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: Illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001529","article-title":"Urinary symptoms in women receiving carboplatin\/paclitaxel for treatment of gynecologic cancers","volume":"30","author":"Strauchon","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120089","article-title":"CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review","volume":"432","author":"Khan","year":"2022","journal-title":"J Neurol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.954468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:26:13Z","timestamp":1662967573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.954468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":40,"alternative-id":["10.3389\/fonc.2022.954468"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.954468","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"954468"}}